TL;DR: The Centers for Medicare & Medicaid Services modified NCD 52 governing therapeutic embolization coverage, with an effective date of January 9, 2026. The policy does not list specific CPT or HCPCS codes, but billing teams need to understand the updated medical necessity criteria now to avoid claim denial.
The CMS therapeutic embolization coverage policy under NCD 52 Medicare covers the procedure for hemorrhage and other conditions amenable to treatment — when reasonable and necessary for the individual patient. Renal embolization for renal adenocarcinoma has been covered since December 15, 1978, for three specific indications. If your team bills therapeutic embolization billing for Medicare patients, this policy revision is the governing document.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Therapeutic Embolization — NCD 52 |
| Policy Code | NCD 52 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | Medium |
| Specialties Affected | Interventional Radiology, Vascular Surgery, Urology, Oncology, General Surgery |
| Key Action | Audit documentation for "reasonable and necessary" medical necessity language before submitting Medicare claims for any therapeutic embolization procedure |
CMS Therapeutic Embolization Coverage Criteria and Medical Necessity Requirements 2026
NCD 52 is the National Coverage Determination governing Medicare coverage of therapeutic embolization under the Centers for Medicare & Medicaid Services physician services benefit. The modified coverage policy, effective January 9, 2026, keeps the core coverage framework in place. But the standard it sets is one your billing team needs to document against precisely.
CMS covers therapeutic embolization in two situations. First, when done for hemorrhage control. Second, for "other conditions amenable to treatment by the procedure" — with the critical qualifier that the procedure must be "reasonable and necessary for the individual patient."
That second bucket is where denials happen. "Amenable to treatment" is not a blank check. You need documentation showing why embolization was the right intervention for this specific patient. Generic procedure notes will not hold up on audit or appeal.
Renal Embolization for Renal Adenocarcinoma
Renal embolization for renal adenocarcinoma carries specific, enumerated coverage indications dating to December 15, 1978. CMS covers it for three purposes:
| # | Covered Indication |
|---|---|
| 1 | To reduce tumor vascularity before surgery (preoperative) |
| 2 | To reduce tumor bulk in inoperable cases |
| 3 | To palliate specific symptoms |
Each of these is a distinct clinical scenario. Your documentation needs to align with one of them explicitly. "Patient has renal adenocarcinoma" is not sufficient. The record should state why the patient was inoperable, or what specific symptoms were being palliated, or how preoperative vascularity reduction was planned.
Medical Necessity Is the Real Test
CMS does not require prior authorization for therapeutic embolization under NCD 52 at the national level. However, your Medicare Administrative Contractor may have a local coverage determination — an LCD — that adds additional documentation or prior auth requirements for specific indications. Check with your MAC before assuming national coverage is sufficient.
The medical necessity standard is "reasonable and necessary for the individual patient." That phrase appears in the policy text and it is the phrase that Medicare reviewers will look for in your records. If your procedure note doesn't speak to that standard, your reimbursement is at risk.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Therapeutic embolization for hemorrhage | Covered | Not specified in NCD 52 | Must be reasonable and necessary for the individual patient |
| Therapeutic embolization for other amenable conditions | Covered | Not specified in NCD 52 | "Reasonable and necessary" medical necessity standard applies; documentation is critical |
| Renal embolization — preoperative tumor vascularity reduction (renal adenocarcinoma) | Covered | Not specified in NCD 52 | Coverage effective December 15, 1978; document surgical intent clearly |
| Renal embolization — tumor bulk reduction, inoperable cases (renal adenocarcinoma) | Covered | Not specified in NCD 52 | Document inoperability in medical record; vague notes will not support the claim |
| Renal embolization — palliation of specific symptoms (renal adenocarcinoma) | Covered | Not specified in NCD 52 | Specify which symptoms; "palliation" without specificity invites denial |
CMS Therapeutic Embolization Billing Guidelines and Action Items 2026
The policy modification is effective January 9, 2026. If your team hasn't reviewed your therapeutic embolization billing workflows against this updated coverage policy, do it now. Here's what to do.
1. Pull your MAC's LCD for therapeutic embolization.
NCD 52 sets the national floor. Your Medicare Administrative Contractor may have an LCD that goes further — adding covered diagnosis codes, prior authorization requirements, or documentation templates. Contact your MAC directly or search the CMS LCD database. Don't assume NCD 52 is the only document that governs your claims.
2. Update your procedure documentation templates.
Your clinical notes need to address "reasonable and necessary for the individual patient" explicitly. Work with your medical director or treating physicians to build this language into procedure note templates. The phrase doesn't need to appear verbatim, but the concept does. Why was this procedure the right choice for this patient? Answer that in the record.
3. Separate your renal adenocarcinoma cases into three buckets.
Preoperative, inoperable/tumor bulk, and palliative are three distinct coverage scenarios. Each requires different supporting documentation. Build a documentation checklist for each one. Treat them as separate claim types even if the procedure code is the same.
4. Audit claims submitted before January 9, 2026 for documentation gaps.
If you have pending appeals or open claims for therapeutic embolization, review them against the updated coverage policy criteria now. A documentation gap that existed before the effective date may still be curable with an addendum. Talk to your billing consultant before you submit or appeal anything with thin documentation.
5. Verify code selection with your MAC — NCD 52 does not list specific CPT or HCPCS codes.
This is the single most operationally awkward part of this policy. CMS does not specify applicable CPT or HCPCS codes in NCD 52 itself. Your charge capture team needs to confirm which procedure codes your MAC accepts for therapeutic embolization claims. If there's any ambiguity about which code maps to which indication, get that answer from your MAC before the claim goes out. A claim denial because of a code-indication mismatch is preventable.
6. If your mix includes oncology patients undergoing renal embolization, loop in your compliance officer.
The three-indication structure for renal adenocarcinoma is specific. If you're billing this in volume, your compliance officer should review your documentation standards against NCD 52 before the January 9, 2026 effective date. This is not a situation where "close enough" holds up on a RAC audit.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Therapeutic Embolization Under NCD 52
NCD 52 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is an unusual and operationally significant gap.
What This Means for Your Billing Team
You cannot pull a code list from the policy document itself. You need to work directly with your Medicare Administrative Contractor to confirm which procedure codes are accepted for therapeutic embolization billing under NCD 52. Your MAC's LCD — if one exists for your jurisdiction — may supply that code list.
Contact your MAC's provider relations line or search the CMS MCD (Medicare Coverage Database) for LCDs tied to therapeutic embolization in your jurisdiction. Do this before the January 9, 2026 effective date.
Why the Absence of Codes Matters
When a coverage policy lacks explicit code assignments, claim processing depends on the MAC's internal logic and any applicable LCDs. That creates regional variability. Two practices in different MAC jurisdictions may get different results on the same procedure with the same documentation.
If you operate across multiple MAC jurisdictions, this is a real risk. Audit your claim results by jurisdiction and flag any patterns of denial. That pattern may tell you that one MAC has issued an LCD that differs from another.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.